A single patient has received the world’s first injection of a gene therapy designed to reverse cellular aging, marking a historic leap in longevity science. On June 9, 2026, Boston-based Life Biosciences announced it dosed its first volunteer with ER-100, a treatment targeting age-related vision loss in glaucoma and NAION patients. The therapy uses three genes to “partially reprogram” aged cells, nudging them toward youthful function without erasing their specialized identity.
Why the Eye Was the First Target
The eye was chosen as the first test site not just for its accessibility, but because the risks are lower than in other organs. Unlike the heart or liver, the optic nerve’s isolation from critical systems reduces the chance of catastrophic side effects—a concern that has long haunted the field. As Matt Kaeberlein, co-founder of longevity-focused Optispan, told Nature, “Reprogramming has a big upside if it can be used safely in people. The technology is still really early, and the potential for catastrophic side effects is high.”
Life Biosciences’ approach builds on decades of research, including work by Harvard Medical School’s David Sinclair, who demonstrated in 2020 that activating these three “Yamanaka Factors” could restore vision in aged mice with glaucoma. The company’s pre-clinical trials in rodents and monkeys showed no serious adverse effects, according to Sharon Rosenzweig-Lipson, the firm’s chief scientific officer. Yet the human trial—cleared by the FDA—is the first test of whether the technique can safely “ameliorate human disease,” as Sinclair put it.
The Science Behind the Shot: Partial Reprogramming Explained
ER-100 doesn’t erase a cell’s identity or revert it to a stem-cell state. Instead, it “partially reprograms” aged cells, restoring epigenetic markers that decline with time. Think of it as a software update for DNA: the therapy reactivates genes that had been silenced by aging, without resetting the cell’s core function. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage,” Sinclair explained to WIRED. “This study is the first chance to test whether restoring that information can actually fix disease in people.”
For more on this story, see Scientists Achieve First High-Precision CRISPR Gene Edits in Human Embryos.
The therapy’s mechanism hinges on the “Yamanaka Factors,” four proteins discovered in 2007 by Nobel laureate Shinya Yamanaka that can turn adult cells into stem cells. Life Biosciences uses three of these factors to avoid full reprogramming—a process that could trigger tumors. Partial reprogramming, as Rosenzweig-Lipson described to Technology Networks, is like “resetting the epigenetic clock” without rewinding the entire tape. Early animal studies showed restored function in optic nerves, but the human trial will determine if the effect translates beyond the lab.
Who’s Backing the Bid to Reverse Aging?
Life Biosciences isn’t alone in chasing this prize. The field has attracted heavyweight investors, including billionaires Jeff Bezos and Sam Altman, who’ve funded startups like Altos Labs and Retro Biosciences. Pharmaceutical giants Eli Lilly and Merck have also bet on the technology: Lilly just participated in a $435 million funding round for New Limit, another company developing cellular reprogramming therapies. “To me, this represents a potential transformational moment—not just for the company, not just for aging biology, but for medicine,” Life Biosciences CEO Jerry McLaughlin told Business Insider.
The financial stakes reflect the ambition. If ER-100 proves safe and effective, it could open the door to treatments for a host of age-related diseases—from fatty liver disease to neurodegenerative disorders. But the path is fraught with uncertainty. Animal studies can’t predict human responses, and the risk of unintended consequences (like cancer) remains. “The technology is still really early,” Kaeberlein warned. “We’re talking about fundamental changes to how cells work.”
What Happens Next: The Trial’s Timeline and Beyond
The first patient will be monitored for six months to assess safety and preliminary efficacy. If the trial proceeds without serious side effects, Life Biosciences plans to expand to 18 adults with glaucoma or NAION. Success could accelerate broader applications—imagine therapies for heart disease, diabetes, or even Alzheimer’s—though those remain years away. “This is more than meets the eye,” Rosenzweig-Lipson noted. “We’re not just targeting vision; we’re testing a platform that could redefine how we treat aging itself.”
For now, the focus is on the eye. If ER-100 restores vision in patients, it could validate partial reprogramming as a viable strategy for other organs. But the bigger question looms: Can aging itself be reversed? The answer may hinge on whether this trial’s results inspire confidence—or caution—in the race to turn back time.
Consult your healthcare provider before considering any experimental treatment. This therapy is not yet approved for general use.
